Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Consolidated Net Income (2016 - 2025)

Rein Therapeutics has reported Consolidated Net Income over the past 10 years, most recently at $7.4 million for Q4 2025.

  • Quarterly Consolidated Net Income fell 16.6% to $7.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.6 million through Dec 2025, up 21.33% year-over-year, with the annual reading at -$9.9 million for FY2025, 26.61% up from the prior year.
  • Consolidated Net Income was $7.4 million for Q4 2025 at Rein Therapeutics, up from -$5.5 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $8.8 million in Q4 2024 and troughed at -$9.0 million in Q2 2024.
  • The 5-year median for Consolidated Net Income is -$6.2 million (2022), against an average of -$4.7 million.
  • The largest YoY upside for Consolidated Net Income was 220.99% in 2024 against a maximum downside of 380.8% in 2024.
  • A 5-year view of Consolidated Net Income shows it stood at -$6.8 million in 2021, then surged by 31.0% to -$4.7 million in 2022, then tumbled by 55.01% to -$7.3 million in 2023, then soared by 220.99% to $8.8 million in 2024, then fell by 16.6% to $7.4 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Consolidated Net Income are $7.4 million (Q4 2025), -$5.5 million (Q3 2025), and -$6.9 million (Q2 2025).